Brian Tanquilut

Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...

Shares of Envision Healthcare Corporation (NYSE: EVHC) were trading notably lower by more than 30 percent Wednesday morning in reaction to the company's disappointing earnings report. Envision Healthcare cited the impact of hurricanes Harvey and Irma for its poor performance in the quarter, but...

Jefferies initiated coverage on Cardinal Health Inc (NYSE: CAH), AmerisourceBergen Corp. (NYSE: ABC) and McKesson Corporation (NYSE: MCK) Wednesday with Hold ratings. Jefferies’ analysis of prices paid by independent pharmacies for generic drugs leads analyst Brian Tanquilut to the conclusion...

Jefferies’ Brian Tanquilut maintains a bullish stance on Walgreens Boots Alliance Inc (NASDAQ: WBA), stating that the stock volatility over the past week, driven by speculations regarding FTC concerns with the pending Rite Aid Corporation (NYSE: RAD) deal, is just near-term “noise....

While mentioning the pullback in CVS Health Corp (NYSE: CVS) shares in recent months, Jefferies’ Brian Tanquilut expressed concern regarding the stock’s outlook for the next 12 months. Tanquilut initiated coverage of the company with a Hold rating and price target of $82. Stock...

Walgreens Boots Alliance Inc (NASDAQ: WBA) and Rite Aid Corporation (NYSE: RAD) shareholders have been in limbo in recent months, as they wait to see whether the proposed merger of the two drugstore chains will be approved by regulators. Earlier this month, FTC commissioner Terrell McSweeny said...

In a report published Friday morning, Jefferies analyst Brian Tanquilut and associate Jason Plagman provided some takeaways from the 2015 Jefferies Healthcare Conference. The analysts walked away with the sense that most companies were optimistic about "their near- and longer-term outlooks as...

Jefferies issued a company note on Tuesday highlighting Catamaran Corp (USA) (NASDAQ: CTRX). Jefferies downgraded Catamaran from Buy to Hold and raised its price target from $58 to $61.50. Analysts Brian Tanquilut and Jason Plagman wrote, "We expect the UnitedHealth Group Inc. (NYSE: UNH) offer to...

In a report published Monday, Jefferies analyst Brian Tanquilut initiated coverage on Envision Healthcare Holdings (NYSE: EVHC) with a Buy rating and $34.00 price target. In the report, Jefferies noted, “We are initiating coverage on EVHC with a Buy rating and a $34 PT based on our view that it is...

In a report published Thursday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Catamaran Corp. (NASDAQ: CTRX) and raised the price target from $65.00 to $70.00. In the report, Jefferies noted, “We have a bullish view on CTRX, especially now that all the overhangs on the name have...